Vienna headquartered lifebrain is through its subsidiaries a leading routine and specialty laboratory testing operator with approximately 220 laboratories across Italy, performing more than 20 million tests annually and serving more than 200 health care facilities. The product portfolio of lifebrain includes seven main product segments in the field of laboratory diagnostics services: clinical chemistry, haematology, immunochemistry, microbiology, molecular biology, cytology and pathology. lifebrain generates revenues in excess of €100 million. Investindustrial now owns 96% of llifebrain.
Wolf Theiss acted for all of the approx. 40 shareholders of ifebrain which were aligned under a specifically designed escrow structure. Michael Havel, CEO of lifebrain, who lead the transaction for the sellers, said: “The Wolf Theiss team headed by Dieter Spranz has been an essential partner of lifebrain from its foundation on. The continuous service and solution oriented advice was certainly instrumental for the successful capital funding and finally completion of this transaction. Especially, we want to thank Clara Gordon for her inexhaustible commitment and efforts which were invaluably supportive to execute this cross-border transaction, despite the complex elements and very tight timeframe.”
The key team of Wolf Theiss advising on this transaction, besides Dieter Spranz (Partner) and Clara Gordon (Senior Associate), included Ivo Stitic (Senior Associate) and Carolin Ziegler (Consultant). Jochen Anweiler (Counsel) advised on Austrian merger control aspects.
Wolf Theiss was responsible for structuring of the sales process, carrying out, respectively coordinating the legal vendor due diligence as well as drafting and negotiation of all agreements. The Italian offices of the international law firm Dentons in Milano and Rome acted as Italian law counsel.